List view / Grid view
Genomics is the branch of molecular biology concerned with the structure, function, evolution, and mapping of genomes.
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
The UK Government has said genomics expertise will be offered to countries around the world to identify new variants of SARS-CoV-2.
TALEN was shown to be almost five times more efficient than CRISPR-Cas9 at locating and editing genes in heterochromatin.
The patient-derived model of non-alcoholic fatty liver disease (NAFLD) accurately reproduced the complex human metabolic pathways involved in the development of the disease.
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
Treating only a few nerve cells with the hyper-interleukin-6 (hIL-6) gene therapy stimulated the regeneration of nerves.
The natural language processing model trained using viral protein sequence data was able to predict promising targets for vaccines against HIV, influenza and coronaviruses.
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
Researchers show that genomic tracking can be used to trace individual virus transmission lineages and could therefore be adopted for future pandemics.
A new study has revealed a range of genomic, proteomic and transcriptomic data about head and neck cancers, presenting possible treatment strategies.
Researchers have used a novel DNA-editing method to convert one base pair to another, increasing the lifespan of mice with progeria.
In this article, Ramya Sriram describes how data science is driving innovations in medical biotechnology and genomics.
17 December 2020 | By Living Systems Institute, University of Exeter
Watch our on-demand webinar where we explore new methods to improve data quality from high-throughput screens. You'll learn about solutions for common problems in drug-target discovery and our keynote speaker will also look at case studies where new approaches to screening have identified high-quality candidate drugs for proliferative diseases.
According to researchers, an interaction between host microRNA and SARS-CoV-2 could be responsible for the range of disease severities.
Cancer researchers have created a new class of drugs to selectively target and destroy myeloid leukaemia cells with TET gene mutations.
